Thomas Shrader, PhD, CFA, is a Managing Director and Healthcare Analyst at BTIG. He provides coverage of the biotechnology sector, with a focus on large and smidcap companies. Prior to BTIG, Mr. Shrader was the Vice President of Strategy and Communications at Intrexon Corporation. Previously, he was a Biotechnology Research Analyst at Stifel. Earlier in his career, Mr. Shrader was on the Biochemistry Faculty at the Albert Einstein College of Medicine. He earned a BA from The Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology.
BackCoverage Area
| Company | Ticker |
|---|---|
| Biogen, Inc. | BIIB |
| Denali Therapeutics Inc. | DNLI |
| Esperion Therapeutics, Inc. | ESPR |
| Verona Pharma plc | VRNA |
| Alector Inc. | ALEC |
| Stoke Therapeutics, Inc. | STOK |
| BridgeBio Pharma, Inc. | BBIO |
| Minerva Neurosciences, Inc. | NERV |
| INmune Bio Inc. | INMB |
| Aldeyra Therapeutics | ALDX |
| Silence Therapeutics | SLN |
| SQZ Biotechnologies Co | SQZ |
| Pliant Therapeutics | PLRX |
| Celularity | CELU |
| Gain Therapeutics, Inc. | GANX |
| Sigilon Therapeutics | SGTX |
| Athira Pharma | ATHA |
| Acumen Pharmaceuticals | ABOS |
| Annexon, Inc. | ANNX |
| Vaxcyte, Inc. | PCVX |
| Biohaven Ltd. | BHVN |